{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T13:49:21Z","timestamp":1744379361752,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005632","name":"Narodowe Centrum Bada\u0144 i Rozwoju","doi-asserted-by":"publisher","award":["POIG.01.04.00-04-219\/12"],"award-info":[{"award-number":["POIG.01.04.00-04-219\/12"]}],"id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007771","name":"Medical University of Silesia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007771","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Schizophrenia is a mental disease that affects approximately 1% of the population. Despite over 100\u00a0years of research, its pathomechanism has still not been clarified. Cognitive deficits, which are one of the symptomatic dimensions of schizophrenia, usually appear a few years before the first psychotic episode. Therefore, this is why they are probably the clinical manifestation of the primary pathomechanism of schizophrenia. It is also supposed that <jats:italic>N<\/jats:italic>-methyl-<jats:sc>d<\/jats:sc>-aspartate receptor (NMDA-R) insufficiency in the prefrontal cortex is responsible for cognitive deficits in schizophrenia. The study aimed to examine whether four selected single nucleotide variants in <jats:italic>GRIN1<\/jats:italic>, <jats:italic>GRIN2A<\/jats:italic> and <jats:italic>GRIN2B<\/jats:italic> encoding NMDA-R subunits, of which two have not been tested before, are linked with the selected clinical phenotype of cognitive dysfunction in schizophrenia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study included the targeted group of 117 patients diagnosed with schizophrenia, all with cognitive deficits and in symptomatic remission. DNA fragments including the studied polymorphisms of the NMDA receptors subunit genes were amplified by polymerase chain reaction and subjected to sequencing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study did not confirm the presence of any of the four selected single nucleotide variants in <jats:italic>GRIN1<\/jats:italic>, <jats:italic>GRIN2A<\/jats:italic> and <jats:italic>GRIN2B<\/jats:italic> subunits of NMDA-R.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The finding indicates that selected single nucleotide variants in GRIN2A and GRIN2B encoding subunits of the NMDA receptor are not associated with the presence of cognitive deficits in schizophrenia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s43440-020-00192-1","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T10:03:03Z","timestamp":1606298583000},"page":"269-277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exploratory study of selected nucleotide variants in GRIN1, GRIN2A and GRIN2B encoding subunits of the NMDA receptor in a targeted group of schizophrenia patients with chronic cognitive impairment"],"prefix":"10.1007","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1665-7344","authenticated-orcid":false,"given":"Marek","family":"Krzystanek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8832-7726","authenticated-orcid":false,"given":"Marek","family":"Asman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9733-7632","authenticated-orcid":false,"given":"Joanna","family":"Witecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2632-1211","authenticated-orcid":false,"given":"Artur","family":"Pa\u0142asz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7309-0121","authenticated-orcid":false,"given":"Ryszard","family":"Wiaderkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"issue":"2","key":"192_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.gene.2013.09.110","volume":"535","author":"S Singh","year":"2014","unstructured":"Singh S, Kumar A, Agarwal S, Phadke SR, Jaiswal Y. Genetic insight of schizophrenia: past and future perspectives. Gene. 2014;535(2):97\u2013100.","journal-title":"Gene"},{"issue":"3","key":"192_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3371\/CSRP.4.3.6","volume":"4","author":"JT Kantrowitz","year":"2010","unstructured":"Kantrowitz JT, Javitt DC. Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin Schizophr Relat Psychoses. 2010;4(3):189\u2013200.","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"192_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.euroneuro.2008.06.005","volume":"18","author":"RD Paz","year":"2008","unstructured":"Paz RD, Tardito S, Atzori M, Tseng KY. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol. 2008;18:773\u201386.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"7","key":"192_CR4","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1176\/appi.ajp.159.7.1183","volume":"159","author":"R Fuller","year":"2002","unstructured":"Fuller R, Nopoulos P, Arndt S, O\u2019Leary D, Ho BC, Andreasen NC. Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. Am J Psychiatry. 2002;159(7):1183\u20139.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"192_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1176\/appi.ajp.157.4.549","volume":"157","author":"RM Bilder","year":"2000","unstructured":"Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000;157(4):549\u201359.","journal-title":"Am J Psychiatry"},{"key":"192_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/neuro.09.036.2009","volume":"3","author":"BR Rund","year":"2009","unstructured":"Rund BR. Is there a degenerative process going on in the brain of people with Schizophrenia? Front Hum Neurosci. 2009;3:36.","journal-title":"Front Hum Neurosci."},{"issue":"Suppl 1","key":"192_CR7","doi-asserted-by":"publisher","first-page":"i171","DOI":"10.1093\/cercor\/bhm069","volume":"17","author":"HY Tan","year":"2007","unstructured":"Tan HY, Callicott JH, Weinberger DR. Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb Cortex. 2007;17(Suppl 1):i171\u201381.","journal-title":"Cereb Cortex"},{"issue":"Suppl 1","key":"192_CR8","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1055\/s-2006-931483","volume":"39","author":"A Carlsson","year":"2006","unstructured":"Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry. 2006;39(Suppl 1):S10\u20134.","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"192_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/schbul\/16.3.425","volume":"16","author":"M Carlsson","year":"1990","unstructured":"Carlsson M, Carlsson A. Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophr Bull. 1990;16(3):425\u201332.","journal-title":"Schizophr Bull"},{"issue":"3\u20134","key":"192_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00213-003-1582-z","volume":"169","author":"JH Krystal","year":"2003","unstructured":"Krystal JH, D\u2019Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl). 2003;169(3\u20134):215\u201333.","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"192_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1124\/mol.109.059865","volume":"77","author":"GJ Marek","year":"2010","unstructured":"Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H. Glutamatergic (N-methyl-d-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol. 2010;77(3):317\u201326.","journal-title":"Mol Pharmacol"},{"issue":"6\u20137","key":"192_CR12","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.neuropharm.2009.02.003","volume":"56","author":"MS Thomsen","year":"2009","unstructured":"Thomsen MS, Christensen DZ, Hansen HH, Redrobe JP, Mikkelsen JD. Alpha(7) nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment. Neuropharmacology. 2009;56(6\u20137):1001\u20139.","journal-title":"Neuropharmacology"},{"key":"192_CR13","first-page":"93","volume-title":"Neurocognitive expression of hypofrontality in long term schizophrenia","author":"M Krzystanek","year":"2011","unstructured":"Krzystanek M, Krupka-Matuszczyk I, Klasik A. Psychiatric disorders\u2014trends and developments. In: Uehara T, editor. Neurocognitive expression of hypofrontality in long term schizophrenia. Rijeka: IntechOpen; 2011. p. 93\u2013106."},{"issue":"6","key":"192_CR14","doi-asserted-by":"publisher","first-page":"E1442","DOI":"10.3390\/ijms20061442","volume":"20","author":"M Krzystanek","year":"2019","unstructured":"Krzystanek M, Pa\u0142asz A. NMDA receptor model of antipsychotic drug-induced hypofrontality. Int J Mol Sci. 2019;20(6):E1442.","journal-title":"Int J Mol Sci"},{"key":"192_CR15","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/sj.mp.4000838","volume":"6","author":"SR Rice","year":"2001","unstructured":"Rice SR, Niu N, Berman DB, Heston LL, Sobell JL. Identification of single nucleotide polymorphisms (SNPs) and other sequence changes and estimation of nucleotide diversity in coding and flanking regions of the NMDAR1 receptor gene in schizophrenic patients. Mol Psychiatry. 2001;6:274\u201384.","journal-title":"Mol Psychiatry"},{"issue":"7","key":"192_CR16","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0006-3223(02)01783-3","volume":"53","author":"S Begni","year":"2003","unstructured":"Begni S, Moraschi S, Bignotti S, Fumagalli F, Rillosi L, Perez J, et al. Association between the G1001C polymorphism in the GRIN1 gene promoter region and schizophrenia. Biol Psychiatry. 2003;53(7):617\u20139.","journal-title":"Biol Psychiatry"},{"key":"192_CR17","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.biopsych.2005.10.023","volume":"59","author":"X Zhao","year":"2006","unstructured":"Zhao X, Li H, Shi Y, Tang R, Chen W, Liu J, et al. Significant association between the genetic variations in the 5-prime end of the N-methyl-d-aspartate receptor subunit gene GRIN1 and schizophrenia. Biol Psychiatry. 2006;59:747\u201353.","journal-title":"Biol Psychiatry"},{"key":"192_CR18","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.ajhg.2016.10.002","volume":"99","author":"SA Swanger","year":"2016","unstructured":"Swanger SA, Chen W, Wells G, Burger PB, Tankovic A, Bhattacharya S, et al. Mechanistic insight into NMDA receptor dysregulation by rare variants in the GluN2A and GluN2B agonist binding domains. Am J Hum Genet. 2016;99:1261\u201380.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"192_CR19","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","volume":"162","author":"NC Andreasen","year":"2005","unstructured":"Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441\u20139.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"192_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s12031-008-9148-5","volume":"38","author":"H Galehdari","year":"2009","unstructured":"Galehdari H, Pooryasin A, Foroughmand A, Daneshmand S, Saadat M. Association between the G1001C polymorphism in the GRIN1 gene promoter and schizophrenia in the Iranian population. J Mol Neurosci. 2009;38(2):178\u201381.","journal-title":"J Mol Neurosci"},{"issue":"4","key":"192_CR21","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000071211","volume":"47","author":"HJ Chiu","year":"2003","unstructured":"Chiu HJ, Wang YC, Liou YJ, Lai IC, Chen JY. Association analysis of the genetic variants of the N-methyl d-aspartate receptor subunit 2b (NR2b) and treatment-refractory schizophrenia in the Chinese. Neuropsychobiology. 2003;47(4):178\u201381.","journal-title":"Neuropsychobiology"},{"issue":"4","key":"192_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/00041444-200112000-00007","volume":"11","author":"CJ Hong","year":"2001","unstructured":"Hong CJ, Yu YW, Lin CH, Cheng CY, Tsai SJ. Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia. Psychiatr Genet. 2001;11(4):219\u201322.","journal-title":"Psychiatr Genet"},{"key":"192_CR23","first-page":"11","volume":"9","author":"M Saadat","year":"2010","unstructured":"Saadat M. N-methyl-d-aspartate receptor NR1 subunit gene (GRIN1) G1001C polymorphism and susceptibility to schizophrenia: a meta-analysis. EXCLI Journal. 2010;9:11\u20136.","journal-title":"EXCLI Journal"},{"issue":"4","key":"192_CR24","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","volume":"41","author":"F Faul","year":"2009","unstructured":"Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149\u201360.","journal-title":"Behav Res Methods"},{"issue":"5","key":"192_CR25","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.pharep.2015.01.017","volume":"67","author":"M Krzystanek","year":"2015","unstructured":"Krzystanek M, Bogus K, Pa\u0142asz A, Krzystanek E, Worthington JJ, Wiaderkiewicz R. Effects of long-term treatment with the neuroleptics haloperidol, clozapine and olanzapine on immunoexpression of NMDA receptor subunits NR1, NR2A and NR2B in the rat hippocampus. Pharmacol Rep. 2015;67(5):965\u20139.","journal-title":"Pharmacol Rep."},{"issue":"5","key":"192_CR26","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.pharep.2016.05.009","volume":"68","author":"M Krzystanek","year":"2016","unstructured":"Krzystanek M, Bogus K, Pa\u0142asz A, Wiaderkiewicz A, Filipczyk \u0141, Rojczyk E, et al. Extended neuroleptic administration modulates NMDA-R subunit immunoexpression in the rat neocortex and diencephalon. Pharmacol Rep. 2016;68(5):990\u20135.","journal-title":"Pharmacol Rep."}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00192-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s43440-020-00192-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00192-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T06:30:17Z","timestamp":1612420217000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s43440-020-00192-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["192"],"URL":"https:\/\/doi.org\/10.1007\/s43440-020-00192-1","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"type":"print","value":"1734-1140"},{"type":"electronic","value":"2299-5684"}],"subject":[],"published":{"date-parts":[[2020,11,25]]},"assertion":[{"value":"23 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}